The United Laboratories International (HKG:3933) obtained approval for the clinical trial application of UBT251 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The drug was developed by The United Bio-Technology (Hengqin), a unit of the firm, and is indicated to treat moderate to severe obstructive sleep apnea with obesity.